13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001560009
Total reported value
$162.6M
$162.6M
9 檔
120.7%
As reported in its official Q3 2025 Form 13F filing, Versant Venture Management, LLC's tracked investment portfolio stood at $162.6M with 9 total positions.
Versant Venture Management, LLC executed strategic sector rebalancing during Q3 2025, establishing 3 new positions while fully exiting 1 holdings and trimming 2 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | Stock-Other | 58.25% | -7.91% | — | |
| 2 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 19.72% | +10.34% | — | |
| 3 | JBIO | Jade Biosciences Inc | Stock-Other | 6.20% | -1.61% | — | |
| 4 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 4.54% | -0.02% | -70.15% | |
| 5 | SKYE | Skye Bioscience Inc | Stock-Other | 3.71% | -0.01% | — | |
| 6 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 3.00% | +0.46% | — | |
| 7 | RPTX | Repare Therapeutics Inc | Stock-Other | 2.19% | — | — | |
| 8 | OVASUSD | Tempest Therapeutics Inc | Stock-Other | 1.31% | -0.13% | — | |
| 9 | ADVMCHF | Adverum Biotechnologies Inc | Stock-Other | 1.08% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SKYE | Skye Bioscience Inc | -1.6% | — | Unchanged |
| 2 | RPTX | Repare Therapeutics Inc | -2.1% | — | Unchanged |
| 3 | ADVMCHF | Adverum Biotechnologies Inc | -2.6% | — | Unchanged |
| 4 | CTNM | Contineum Therapeutics Inc-a | -7.6% | — | Trim |
| 5 | CRSP | CRISPR Therapeutics AG | -23.6% | -70.15% | Trim |
| 6 | GLUE | Monte Rosa Therapeutics Inc | -23.8% | — | Unchanged |
| 7 | LENZ | Lenz Therapeutics Inc | — | NEW | New buy |
| 8 | JBIO | Jade Biosciences Inc | — | NEW | New buy |
| 9 | OVASUSD | Tempest Therapeutics Inc | — | NEW | New buy |
| 10 | TPST | Tempest Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Versant Venture Management, LLC reported a total U.S. public equity portfolio value of $162.6M across 9 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LENZ, GLUE, JBIO) accounted for 120.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
LENZ
市值: $123.8M
Top Position Liquidated / Trimmed
TPST
前期市值: $2.6M
During Q3 2025, Versant Venture Management, LLC's top holdings by market value included LENZ (58.3%)、GLUE (19.7%)、JBIO (6.2%). The largest single position, LENZ, represented 58.3% of total portfolio value.
In Q3 2025, Versant Venture Management, LLC made 6 total portfolio adjustments, initiating 3 new buys, adding to 0 positions, trimming 2 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.